W. Ruprecht Wiedemeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
W. Ruprecht Wiedemeyer has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Barbie Taylor-Harding
Women's Cancer Program at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publicationsBeth Y. Karlan
Women's Cancer Program at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publicationsDong-Joo Cheon
Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publications- Jessica A. Beach
Department of Biology, California State University Northridge, Northridge, CA 91330-8303, USA
2 shared publications Lindsay Spurka
Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publicationsSandra Orsulic
Women's Cancer Program at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publications
Latest Publications
- Open Access
- 17 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (16) , 26200-26220
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
- 17 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (16) , 26200-26220
Open AccessGlucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
- 1 October 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (1) , 152-158
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
- 1 October 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (1) , 152-158
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
- Open Access
- 22 December 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (2) , 696-714
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- 22 December 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (2) , 696-714
Open AccessCyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- Open Access
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 34
Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
Resistance to platinum chemotherapy is one of the main factors driving ovarian cancer mortality, and overcoming platinum resistance is considered one of the greatest challenges in ovarian cancer research. Genetic and functional evidence points to the homologous recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main determinants of response to platinum therapy. BRCA-mutant ovarian cancers are especially sensitive to platinum, associated with better survival, and amenable to PARP inhibitor treatment. Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high grade serous ovarian cancers (HGSOCs). We review the molecular signaling pathways that converge on BRCA1 and BRCA2, their activation status in ovarian cancer, and therapeutic options to modulate BRCA function. Several recent publications demonstrate efficient chemosensitization of BRCA-proficient cancers by combining targeted therapy with standard platinum-based agents. Due to its inherent genomic heterogeneity, molecularly defined subgroups of HGSOC may require different approaches. We seek to provide an overview of available agents and their potential use to reverse platinum resistance by inhibiting the HR system, either directly or indirectly, by targeting oncogenic activators of HR.
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 34
Open AccessReversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
Resistance to platinum chemotherapy is one of the main factors driving ovarian cancer mortality, and overcoming platinum resistance is considered one of the greatest challenges in ovarian cancer research. Genetic and functional evidence points to the homologous recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main determinants of response to platinum therapy. BRCA-mutant ovarian cancers are especially sensitive to platinum, associated with better survival, and amenable to PARP inhibitor treatment. Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high grade serous ovarian cancers (HGSOCs). We review the molecular signaling pathways that converge on BRCA1 and BRCA2, their activation status in ovarian cancer, and therapeutic options to modulate BRCA function. Several recent publications demonstrate efficient chemosensitization of BRCA-proficient cancers by combining targeted therapy with standard platinum-based agents. Due to its inherent genomic heterogeneity, molecularly defined subgroups of HGSOC may require different approaches. We seek to provide an overview of available agents and their potential use to reverse platinum resistance by inhibiting the HR system, either directly or indirectly, by targeting oncogenic activators of HR.